The Changing Landscape of Medicaid Managed Care Trends

By HEOR Staff Writer

December 4, 2023

The Rising Influence of Medicaid Managed Care Trends

Medicaid Managed Care (MMC) has seen a significant surge in recent years. As of 2020, MMC insured a whopping 70% of Medicaid beneficiaries, equating to 57 million individuals. This system relies on a private insurer to cover a beneficiary’s medical care in return for fixed payments from state Medicaid agencies. A critical function of MMC insurers is to negotiate prices with hospitals, a process that directly impacts government health expenditures and the access to care for Medicaid beneficiaries.

Unveiling the Mystery of MMC Prices

Despite the importance of MMC prices, little information is available on the subject. To shed light on this, a comprehensive study was conducted using hospitals’ self-disclosed pricing information. The data was obtained from Turquoise Health as of July 3, 2023, which compiles prices reported by hospitals in compliance with the Hospital Price Transparency rule.

The Variation in MMC Prices

This study included Medicaid Managed Care trend prices reported by 1487 general acute care hospitals. Findings showed that MMC prices varied across outpatient service types and states. For instance, the median MMC prices for surgery and medicine were highest in North Dakota and lowest in West Virginia. Similarly, MMC prices for imaging were highest in Utah and lowest in Wisconsin. Furthermore, MMC prices for Emergency Department visits were highest in Washington, DC, and lowest in Wisconsin.

Implications and Future Directions

Contrary to popular belief, Medicaid prices are not always lower than Medicare prices. This study revealed that MMC outpatient hospital prices can sometimes exceed Medicare rates, particularly for imaging services. These findings suggest that MMC hospital prices could significantly affect government health expenditures and the access to care for Medicaid beneficiaries. Further research is needed to explore the causes of variation in MMC hospital prices, including potential market and policy factors.

Reference url

Recent Posts

Bridging Analyses: The Role of Cost Per Event Avoided in Evaluating GLP-1 Agonists

By João L. Carapinha

March 17, 2026

This editorial by Petrou et al., published in the Journal of Medical Economics, critiques escalating pharmaceutical expenditures amid new therapies like glucagon-like peptide-1 (GLP-1) receptor agonists for ty...
EU Medicines Regulation Achievements: EMA’s 2025 Highlights and Future Directions

By HEOR Staff Writer

March 16, 2026

The European Medicines Agency (EMA) Management Board highlights at its March 2026 meeting a robust year, with the adoption of the 2025 annual report detailing 104 positive recommendations for new hu...
European Cancer Care: Balancing Economic Stability with Improved Survival Rates

By João L. Carapinha

March 12, 2026

European Cancer Care has achieved substantial improvements in survival rates without a disproportionate escalation in health budgets, as evidenced by the